294 related articles for article (PubMed ID: 29719138)
1. Mannose and Mannose-6-Phosphate Receptor-Targeted Drug Delivery Systems and Their Application in Cancer Therapy.
Dalle Vedove E; Costabile G; Merkel OM
Adv Healthc Mater; 2018 Jul; 7(14):e1701398. PubMed ID: 29719138
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new mannose 6-phosphate analogues.
Vidal S; Garcia M; Montero JL; Morère A
Bioorg Med Chem; 2002 Dec; 10(12):4051-6. PubMed ID: 12413858
[TBL] [Abstract][Full Text] [Related]
5. Targeting carbon nanotubes against cancer.
Fabbro C; Ali-Boucetta H; Da Ros T; Kostarelos K; Bianco A; Prato M
Chem Commun (Camb); 2012 Apr; 48(33):3911-26. PubMed ID: 22428156
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of apoptosis in MCF7 cancer-cell by targeted liposomes functionalised with mannose-6-phosphate.
Minnelli C; Cianfruglia L; Laudadio E; Galeazzi R; Pisani M; Crucianelli E; Bizzaro D; Armeni T; Mobbili G
J Drug Target; 2018 Mar; 26(3):242-251. PubMed ID: 28795851
[TBL] [Abstract][Full Text] [Related]
7. Mannose-6-phosphate/insulin-Like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells.
Greupink R; Bakker HI; van Goor H; de Borst MH; Beljaars L; Poelstra K
Pharm Res; 2006 Aug; 23(8):1827-34. PubMed ID: 16850269
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification, and characterization of human mannose-6-phosphate receptor - Extra cellular domain from a stable cell line utilizing a small molecule biomimetic of the mannose-6-phosphate moiety.
Dwyer B; Lundberg D; Iskenderian A; Strack-Logue B; Pescatore B; Norton AW; Xu J; Meiyappan M; Concino MF; Zhang B
Protein Expr Purif; 2020 Jun; 170():105589. PubMed ID: 32027983
[TBL] [Abstract][Full Text] [Related]
9. Mannose 6-phosphate receptor targeting and its applications in human diseases.
Gary-Bobo M; Nirdé P; Jeanjean A; Morère A; Garcia M
Curr Med Chem; 2007; 14(28):2945-53. PubMed ID: 18220730
[TBL] [Abstract][Full Text] [Related]
10. Biosynthetic labeling of beta-hexosaminidase B: inhibition of the cellular uptake of lysosomal secretions containing [3H]hexosaminidase B by insulin-like growth factor-II in rat C6 glial cells.
Kessler U; Aumeier S; Funk B; Kiess W
Mol Cell Endocrinol; 1992 Dec; 90(1):147-53. PubMed ID: 1301395
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
Cadete A; Alonso MJ
Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
[TBL] [Abstract][Full Text] [Related]
12. Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications.
Hu J; Wei P; Seeberger PH; Yin J
Chem Asian J; 2018 Nov; 13(22):3448-3459. PubMed ID: 30251341
[TBL] [Abstract][Full Text] [Related]
13. Biological function, regulatory mechanism, and clinical application of mannose in cancer.
Jin H; Liu X; Liu HX
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188970. PubMed ID: 37657682
[TBL] [Abstract][Full Text] [Related]
14. High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor.
Hartman MA; Kreiling JL; Byrd JC; MacDonald RG
FEBS J; 2009 Apr; 276(7):1915-29. PubMed ID: 19236480
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.
Byrd JC; MacDonald RG
J Biol Chem; 2000 Jun; 275(25):18638-46. PubMed ID: 10764735
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
17. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
18. The cation-independent mannose-6-phosphate receptor binds to soluble GPI-linked proteins via mannose-6-phosphate.
Green PJ; Ferguson MA; Robinson PJ; Feizi T
FEBS Lett; 1995 Feb; 360(1):34-8. PubMed ID: 7875296
[TBL] [Abstract][Full Text] [Related]
19. Cation-independent mannose 6-phosphate and 78 kDa receptors for lysosomal enzyme targeting are located in different cell compartments.
González-Noriega A; Michalak C; Antonio Sosa Melgarejo J
Biochim Biophys Acta; 2005 Aug; 1745(1):7-19. PubMed ID: 16085051
[TBL] [Abstract][Full Text] [Related]
20. Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters (mannose 6-phosphate N-acetylglucosamine ester).
Chavez CA; Bohnsack RN; Kudo M; Gotschall RR; Canfield WM; Dahms NM
Biochemistry; 2007 Nov; 46(44):12604-17. PubMed ID: 17927214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
